HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients. (Q53851017)
Jump to navigation
Jump to search
scientific article published on 9 April 2005
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients. |
scientific article published on 9 April 2005 |
Statements
HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients. (English)
1 reference
Kadri Altundag
1 reference
Ozden Altundag
1 reference
Yavuz S Silay
1 reference
Bulent Ozcakar
1 reference
9 April 2005
1 reference
1 reference
49
1 reference
2
1 reference
279-280
1 reference
Identifiers
1 reference